Icotrokinra vs Thymosin Alpha-1
Overview
Icotrokinra is primarily a immune support peptide, while Thymosin Alpha-1 is used for healing & recovery.
This page compares Icotrokinra and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Thymosin Alpha-1 | |
|---|---|---|
| Category | Immune Support | Healing & Recovery |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | — | 1.6-3.2 mg |
| Frequency | — | twice-weekly |
| Reported benefits | — | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | — | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Thymosin Alpha-1 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Typical dosing for Icotrokinra is not catalogued. Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Thymosin Alpha-1?
- Icotrokinra is primarily a immune support peptide, while Thymosin Alpha-1 is used for healing & recovery. Icotrokinra is FDA-approved for one or more indications, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Icotrokinra and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Thymosin Alpha-1 FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references